European Archives of Oto-Rhino-Laryngology

, Volume 274, Issue 3, pp 1187–1196 | Cite as

Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria

  • Sofia WaissbluthEmail author
  • Emilia Peleva
  • Sam J. Daniel
Review Article


The antineoplastic agent’s cisplatin and carboplatin are widely used as they are highly effective. Unfortunately, ototoxicity is a frequently encountered side effect of platinum-based chemotherapy. Clinically, patients generally develop a progressive, bilateral, and irreversible sensorineural hearing loss. With rising cancer survival rates, a greater proportion of patients are living with the side effects of their chemotherapy treatments. Consequently, the quality of life of cancer survivors has now become a major concern for clinicians. Various classification systems are currently available to grade side effects and provide a guideline for subsequent treatments. An extensive review of the literature revealed that a variety of criteria are used worldwide for grading platinum-induced hearing loss in children and adults, including the National Cancer Institute criteria, Brock’s grading system, the American Speech-Hearing-Language Association criteria, the World Health Organization criteria, the Pediatric Oncology Group criteria, and the Muenster classification. Less commonly used criteria include the Chang classification, the Functional Hearing Loss scale, the HIT system (German Hirntumor study grading system), and most recently, the International Society of Pediatric Oncology Boston ototoxicity grading scale. The objective of this review is to evaluate the commonly used ototoxicity criteria and discuss their benefits and limitations.


Ototoxicity Hearing loss Platinum Cisplatin Criteria Grade 


Compliance with ethical standards

Conflict of interest

All authors declare they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    National Institutes of Health (NIH) (2013). Fact sheet—cancer. Accessed 21 Mar 2016
  2. 2.
    Helt-Cameron J, Allen JP (2009) Cisplatin ototoxicity in children: implications for primary care providers. Pediatr Nurs 35:121–127PubMedGoogle Scholar
  3. 3.
    Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9–23CrossRefPubMedGoogle Scholar
  4. 4.
    Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219:177–186CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369CrossRefPubMedGoogle Scholar
  6. 6.
    Herrmann J, Yang EH, Iliescu CA et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133:1272–1289CrossRefPubMedGoogle Scholar
  7. 7.
    Ciccone MM, Cortese F, Pinto M et al (2012) Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. Atherosclerosis 225:511–516CrossRefPubMedGoogle Scholar
  8. 8.
    Carleton BC, Ross CJ, Pussegoda K et al (2014) Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther 96:296–298CrossRefPubMedGoogle Scholar
  9. 9.
    Xu H, Robinson GW, Huang J et al (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47:263–266CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lanvers-Kaminsky C, Sprowl JA, Malath I et al (2015) Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16:323–332CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schroeder L, Petrou S, Kennedy C et al (2006) The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics 117:1101–1112CrossRefPubMedGoogle Scholar
  12. 12.
    Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181CrossRefPubMedGoogle Scholar
  13. 13.
    National Institutes of Health (NIH) (2013). Adverse Events/CTCAE. Accessed 21 Mar 2016
  14. 14.
    da Silva AM, Latorre MRD, Cristofani LM et al (2007) The prevalence of hearing loss in children and adolescents with cancer. Braz J Otorhinolaryngol 73:608–614CrossRefPubMedGoogle Scholar
  15. 15.
    Neuwelt EA, Brock P (2010) Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630–1632CrossRefPubMedGoogle Scholar
  16. 16.
    Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596CrossRefPubMedGoogle Scholar
  17. 17.
    Chang KW, Chinosornvatana N (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788–1795CrossRefPubMedGoogle Scholar
  18. 18.
    Knight KR, Kraemer DF, Winter C et al (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190–1195CrossRefPubMedGoogle Scholar
  19. 19.
    Bertolini P, Lassalle M, Mercier G et al (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–655CrossRefGoogle Scholar
  20. 20.
    Brock PR, Bellman SC, Yeomans EC et al (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300CrossRefPubMedGoogle Scholar
  21. 21.
    Orgel E, Jain S, Ji L et al (2012) Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 58:953–958CrossRefPubMedGoogle Scholar
  22. 22.
    Marina N, Chang KW, Malogolowkin M et al (2005) Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group Study. Cancer 104:841–847CrossRefPubMedGoogle Scholar
  23. 23.
    Schultz C, Goffi-Gomez MVS, Liberman PHP et al (2009) Report on hearing loss in oncology. Braz J Otorhinolaryngol 75:634–641PubMedGoogle Scholar
  24. 24.
    Kushner BH, Budnick A, Kramer K et al (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417–422CrossRefPubMedGoogle Scholar
  25. 25.
    American Speech-Language-Hearing Association (1994) Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. Accessed 21 Mar 2016
  26. 26.
    Dutta A, Venkatesh MD, Kashyap RC (2005) Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 57:226–228PubMedPubMedCentralGoogle Scholar
  27. 27.
    World Health Organization (1991). Report of the informal working group on prevention of deafness and hearing impairment, programme planning. WHO/PDH/91.1Google Scholar
  28. 28.
    Smith AW (2001) WHO activities for prevention of deafness and hearing impairment in children. Scand Audiol Suppl 53:93–100CrossRefGoogle Scholar
  29. 29.
    Zuur CL, Simis YJ, Lansdaal PE et al (2007) Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25:3759–3765CrossRefPubMedGoogle Scholar
  30. 30.
    Stöhr W, Langer T, Kremers A et al (2005) Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005(23):201–207CrossRefGoogle Scholar
  31. 31.
    Lee AW, Yau TK, Wong DHM et al (2005) Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys 63:1331–1338CrossRefPubMedGoogle Scholar
  32. 32.
    Huang E, Teh BS, Strother DR (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605CrossRefPubMedGoogle Scholar
  33. 33.
    Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG (2007) The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy. HNO 55:299–306CrossRefPubMedGoogle Scholar
  34. 34.
    Lafay-Cousin L, Purdy E, Huang A et al (2013) Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr Blood Cancer 60:287–292CrossRefPubMedGoogle Scholar
  35. 35.
    Katzenstein HM, Chang K, Krailo M et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–5835CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Spracklen TF, Whitehorn H, Vorster AA, Ramma L, Dalvie S, Ramesar RS (2014) Genetic variation in Otos is associated with cisplatin-induced ototoxicity. Pharmacogenomics 15:1667–1676CrossRefPubMedGoogle Scholar
  37. 37.
    Peleva E, Emami N, Alzahrani M et al (2014) Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 61:2012–2017CrossRefPubMedGoogle Scholar
  38. 38.
    Lewis MJ, DuBois SG, Fligor B et al (2009) Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387–391CrossRefPubMedGoogle Scholar
  39. 39.
    Lannering B, Rutkowski S, Doz F et al (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187–3193CrossRefPubMedGoogle Scholar
  40. 40.
    Sakamoto M, Kaga K, Kamio T (2000) Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg 122:828–833CrossRefPubMedGoogle Scholar
  41. 41.
    Brock PR, Knight KR, Freyer DR et al (2012) Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30:2408–2417CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hagleitner MM, Coenen MJ, Patino-Garcia A et al (2014) Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 9:e115869CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bass JK, Huang J, Onar-Thomas A et al (2014) Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 61:601–605CrossRefPubMedGoogle Scholar
  44. 44.
    Gurney JG, Bass JK (2012) New International Society of Pediatric Oncology Boston Ototoxicity Grading Scale for pediatric oncology: still room for improvement. J Clin Oncol 30:2303–2306CrossRefPubMedGoogle Scholar
  45. 45.
    Abujamra AL, Escosteguy JR, Dall’Igna C et al (2013) The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 60:474–478CrossRefPubMedGoogle Scholar
  46. 46.
    Davis H, Silverman SR (1978) Hearing and deafness. Holt, Rinehart & Winston, New YorkGoogle Scholar
  47. 47.
    Lanvers-Kaminsky C, Krefeld B, Dinnesen AG et al (2006) Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47:183–193CrossRefPubMedGoogle Scholar
  48. 48.
    Qaddoumi I, Bass JK, Wu J et al (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034–1041CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Sofia Waissbluth
    • 1
    Email author
  • Emilia Peleva
    • 2
  • Sam J. Daniel
    • 3
  1. 1.Department of OtolaryngologyPontificia Universidad Católica de ChileSantiagoChile
  2. 2.King’s College LondonLondonUK
  3. 3.Department of Otolaryngology-Head and Neck SurgeryMcGill UniversityMontrealCanada

Personalised recommendations